Patents by Inventor Ichiro Hijikuro
Ichiro Hijikuro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230105725Abstract: The present invention provides a highly safe non-lamellar liquid crystal-forming composition. The present invention relates to a non-lamellar liquid crystal-forming composition comprising a phospholipid and an amphipathic compound represented by the following general formula (I), wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes the integer 1 or 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group having one or more hydroxyl groups, and wherein the composition has an increased biocompatibility by the phospholipid.Type: ApplicationFiled: January 27, 2021Publication date: April 6, 2023Inventors: Yasuhiko TABATA, Takahide MURAKAMI, Hiroaki TODO, Shoko ITAKURA, Kenji SUGIBAYASHI, Ichiro HIJIKURO, Masahisa TANOMURA
-
Publication number: 20210330794Abstract: The present invention relates to an external preparation that is well retained on a living body surface and is capable of increasing drug permeability, in particular, an external preparation comprising a non-lamellar liquid crystal-forming lipid and a drug.Type: ApplicationFiled: September 9, 2019Publication date: October 28, 2021Inventors: Kenji SUGIBAYASHI, Hiroaki TODO, Ichiro HIJIKURO, Masahisa TANOMURA, Sayaka MORI
-
Publication number: 20200282101Abstract: The purpose of the invention is to provide a tumor sealant to be used for therapy that enables curative treatment, by improving an extremely simple, minimally-invasive therapy consisting of starving tumor cells without radiation exposure or causing serious side effects by drugs. The invention provides a tumor sealant that utilizes the EPR effect specific to tumor cells, that covers the tumor cells of each tissue by particles that permeate only tumor blood vessels and accumulate and settle in the tumor, that does not release angiogenesis-inducing factors, that does not separate tumor cells having improved mobility in a hypoxic state and move them to another location, that permeates gaps of from 50 nm to 500 nm of the tumor vascular endothelial cells, and that biodegrades after adhering to the tumor cells and extracellular matrix near the gaps.Type: ApplicationFiled: December 16, 2016Publication date: September 10, 2020Applicants: MediGear International Corporation, Tokyo Institute of Technology, Farnex IncorporatedInventors: Shinae Kondoh, Takahiro Kuchimaru, Takeo Tanaka, Shoko Itakura, Ichiro Hijikuro
-
Patent number: 9399635Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.Type: GrantFiled: April 11, 2012Date of Patent: July 26, 2016Assignee: GREEN TECH CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
-
Publication number: 20160067208Abstract: The present invention relates to an adhesion preventing agent comprising an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, AA: AA denotes a single bond or double bond, and R denotes a hydrophilic group having two or more hydroxyl groups.Type: ApplicationFiled: April 2, 2014Publication date: March 10, 2016Inventors: Yasuhiko TABATA, Kenjiro Hirai, Ichiro HIJIKURO, Masahisa TANOMURA, Sayaka MORI
-
Patent number: 8962674Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.Type: GrantFiled: November 30, 2007Date of Patent: February 24, 2015Assignees: Tokyo Institute of Technology, Kyoto UniversityInventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome
-
Publication number: 20140194536Abstract: The present invention relates to a liquid crystal compound that can be used as a base for injection formulations. The present invention provides an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol; as well as a base for injection formulations and depot formulation comprising the same.Type: ApplicationFiled: February 28, 2014Publication date: July 10, 2014Applicant: Chemgenesis IncorporatedInventors: Yutaka Ikeda, Jun Yamashita, Ichiro Hijikuro, Satoshi Imuta, Yasuhiro Hiroki, Takashi Takahashi
-
Patent number: 8703922Abstract: The present invention relates to a liquid crystal compound that can be used as a base for injection formulations. The present invention provides an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol; as well as a base for injection formulations and depot formulation comprising the same.Type: GrantFiled: December 27, 2010Date of Patent: April 22, 2014Assignee: Chemgenesis IncorporatedInventors: Yutaka Ikeda, Jun Yamashita, Ichiro Hijikuro, Satoshi Imuta, Yasuhiro Hiroki, Takashi Takahashi
-
Patent number: 8686024Abstract: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group.Type: GrantFiled: February 3, 2010Date of Patent: April 1, 2014Assignees: Kyoto University, Tokyo Institute of TechnologyInventors: Hachiro Sugimoto, Jun Takahashi, Takashi Takahashi, Ichiro Hijikuro
-
Publication number: 20140088029Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.Type: ApplicationFiled: April 11, 2012Publication date: March 27, 2014Applicant: PHARMA EIGHT CO., LTD.Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
-
Patent number: 8552220Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.Type: GrantFiled: May 27, 2009Date of Patent: October 8, 2013Assignees: Tokyo Institute of Technology, Kyoto UniversityInventors: Hachiro Sugimoto, Takashi Takahashi, Ichiro Hijikuro, Michiaki Okuda
-
Publication number: 20120264923Abstract: The present invention relates to a liquid crystal compound that can be used as a base for injection formulations. The present invention provides an amphipathic compound having the following general formula (I): wherein X and Y each denotes a hydrogen atom or together denote an oxygen atom, n denotes an integer from 0 to 2, m denotes the integer 1 or 2, and R denotes a hydrophilic group generated by removal of one hydroxyl group from any one selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol; as well as a base for injection formulations and depot formulation comprising the same.Type: ApplicationFiled: December 27, 2010Publication date: October 18, 2012Applicant: Chemgenesis IncorporatedInventors: Yutaka Ikeda, Jun Yamashita, Ichiro Hijikuro, Satoshi Imuta, Yasuhiro HIroki, Takashi Takahashi
-
Publication number: 20110294850Abstract: The present invention provides a novel indoline derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or a salt thereof represented by the following formula (1) that has an excellent butyrylcholinesterase inhibitory activity. In the formula, R1 represents an alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group, an arylalkyl group, a heteroarylalkyl group, a cycloalkylalkyl group, a heterocycloalkylalkyl group, a dihydrofurylalkyl group, an alkenyl group, a tetrahydronaphthyl group, or an indanyl group; R2 represents a hydrogen atom, an alkyl group, an arylalkyl group, a cycloalkylalkyl group, a heteroarylalkyl group, a heterocycloalkylalkyl group, an aryl group, or an acyl group; R3 each independently represents a hydrogen atom, an alkyl group, or a dialkylaminocarbonyl group; R4 each independently represents a hydrogen atom or an alkyl group; and R5 represents a hydrogen atom or an alkyl group.Type: ApplicationFiled: February 3, 2010Publication date: December 1, 2011Applicants: TOKYO INSTITUTE OF TECHNOLOGY, KYOTO UNIVERSITYInventors: Hachiro Sugimoto, Jun Takahashi, Takashi Takahashi, Ichiro Hijikuro
-
Publication number: 20110082295Abstract: To develop a highly safe measure to treat Alzheimer's disease using a secretase-inhibiting substance, there is provided a compound represented by the following general formula (I) or a salt thereof: wherein A represents a phenyl group or the like, R1 represents a chlorine atom, a bromine atom, or a nitro group or the like, R2, R3, R4, and R5 each represent a hydrogen atom or the like, and L represents CH2—CH2 or CH?CH.Type: ApplicationFiled: May 27, 2009Publication date: April 7, 2011Applicants: Tokyo Institute of Technology, Kyoto UniversityInventors: Hachiro Sugimoto, Takashi Takahashi, Ichiro Hijikuro, Michiaki Okuda
-
Publication number: 20100048901Abstract: The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on A? aggregation, a degradative effect on A? aggregates, an inhibitory effect on ?-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.Type: ApplicationFiled: November 30, 2007Publication date: February 25, 2010Applicants: TOKYO INSTITUTE OF TECHNOLOGY, Kyoto UniversityInventors: Takashi Takahashi, Ichiro Hijikuro, Hachiro Sugimoto, Takeshi Kihara, Yoshiari Shimmyo, Tetsuhiro Niidome